WallStreetZenWallStreetZen

NASDAQ: FTH
Faeth Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for FTH

Based on 3 analysts offering 12 month price targets for Faeth Therapeutics Inc

Min Forecast
$50.00+200.3%
Avg Forecast
$53.33+220.32%
Max Forecast
$55.00+230.33%

Should I buy or sell FTH stock?

Based on 3 analysts offering ratings for Faeth Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although FTH's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates FTH as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their FTH stock forecasts and price targets.

FTH stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-06-15
lockedlocked$00.00+00.00%2026-05-28
lockedlocked$00.00+00.00%2026-05-22

1 of 1

Forecast return on equity

Is FTH forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is FTH forecast to generate an efficient return on assets?

Company
-7.93%
Industry
27.65%
FTH is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

FTH earnings per share forecast

What is FTH's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$6.27
Avg 2 year Forecast
-$8.11
Avg 3 year Forecast
-$6.71

FTH revenue forecast

What is FTH's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$25.8M

FTH vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
FTH$16.65$53.33+220.32%Strong Buy
MRKR$1.35N/AN/A
PTN$12.25N/AN/A
NRSN$0.71$8.50+1,105.67%Strong Buy
CELU$0.80N/AN/A
View Top Biotech Stocks

Faeth Therapeutics Stock Forecast FAQ

Is Faeth Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: FTH) stock is to Strong Buy FTH stock.

Out of 3 analysts, 3 (100%) are recommending FTH as a Strong Buy, 0 (0%) are recommending FTH as a Buy, 0 (0%) are recommending FTH as a Hold, 0 (0%) are recommending FTH as a Sell, and 0 (0%) are recommending FTH as a Strong Sell.

If you're new to stock investing, here's how to buy Faeth Therapeutics stock.

What is FTH's earnings growth forecast for 2026-2028?

(NASDAQ: FTH) Faeth Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.71%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.13%.

Faeth Therapeutics's earnings in 2026 is -$184,458,000.On average, 6 Wall Street analysts forecast FTH's earnings for 2026 to be -$8,417,996, with the lowest FTH earnings forecast at -$12,532,924, and the highest FTH earnings forecast at -$3,903,035. On average, 7 Wall Street analysts forecast FTH's earnings for 2027 to be -$10,889,717, with the lowest FTH earnings forecast at -$16,346,720, and the highest FTH earnings forecast at -$5,598,175.

In 2028, FTH is forecast to generate -$8,999,727 in earnings, with the lowest earnings forecast at -$12,769,642 and the highest earnings forecast at -$4,191,955.

What is FTH's revenue growth forecast for 2026-2028?

(NASDAQ: FTH) Faeth Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.97%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.92%.

Faeth Therapeutics's revenue in 2026 is $0.On average, 5 Wall Street analysts forecast FTH's revenue for 2026 to be $0, with the lowest FTH revenue forecast at $0, and the highest FTH revenue forecast at $0. On average, 5 Wall Street analysts forecast FTH's revenue for 2027 to be $0, with the lowest FTH revenue forecast at $0, and the highest FTH revenue forecast at $0.

In 2028, FTH is forecast to generate $34,561,690 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $71,156,422.

What is FTH's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: FTH) forecast ROA is -7.93%, which is lower than the forecast US Biotechnology industry average of 27.65%.

What is FTH's Price Target?

According to 3 Wall Street analysts that have issued a 1 year FTH price target, the average FTH price target is $53.33, with the highest FTH stock price forecast at $55.00 and the lowest FTH stock price forecast at $50.00.

On average, Wall Street analysts predict that Faeth Therapeutics's share price could reach $53.33 by Jun 15, 2027. The average Faeth Therapeutics stock price prediction forecasts a potential upside of 220.32% from the current FTH share price of $16.65.

What is FTH's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: FTH) Faeth Therapeutics's current Earnings Per Share (EPS) is -$142.72. On average, analysts forecast that FTH's EPS will be -$6.27 for 2026, with the lowest EPS forecast at -$9.34, and the highest EPS forecast at -$2.91. On average, analysts forecast that FTH's EPS will be -$8.11 for 2027, with the lowest EPS forecast at -$12.18, and the highest EPS forecast at -$4.17. In 2028, FTH's EPS is forecast to hit -$6.71 (min: -$9.52, max: -$3.12).

What is FTH's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: FTH) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.